🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Procter & Gamble Health Limited PGHL NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.pghealthindia.com
Company Profile ↓
₹5,048.00
-17.35% 1Y
Mkt Cap₹8,379.37 Cr
P/E23.46
P/B16.47
Div. Yield3.01%
52W High₹6,864.51
52W Low₹4,741.31
Book Value₹316.00
EPS (TTM)₹215.19

Company Overview

Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 62.3%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 76.8%.

Consistent Profit Growth

Net profit has compounded at 19.3% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 23.5, below the sector median of 36.4.

Healthy Margins

Maintains a net profit margin of 24.9%.

Dividend Income

Offers a dividend yield of 3.01%.

Recent Developments

  • Mar 2026 Revenue of ₹1,407.97 Cr (+24.7% YoY); net profit ₹326.91 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +7.4%, earnings -4.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.8%, profit CAGR 19.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.84%
1 Year:7.40%

Compounded Profit Growth

5 Years:19.30%
1 Year:-4.90%

Stock Price Performance

1 Year:-17.35%
6 Months:-2.27%
3 Months:-24.20%
1 Month:-8.28%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 14% of range
₹4,741.31 ₹6,864.51
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Death Cross1d ago
  • RSI (14)32.48 · Neutral
Price Performance
1M-8.28%
3M-24.20%
6M-2.27%
1Y-17.35%
Valuation vs Sector

P/E of 23.46 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 62.3%.
  • Healthy ROCE of 76.8%.
  • Excellent profit margin of 24.9%.
  • Profit CAGR of 19.3% over 5 years.
  • Attractive dividend yield of 3.01%.
  • Generates positive free cash flow.

CONS

  • Trading 26.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
23.46
Industry PE
36.43
Forward P/E
20.51
PEG Ratio
-
Book Value
₹316.00
Price to Book
16.47
P/S
6.03
EV/EBITDA
27.04
Dividend Yield
3.01%

Growth (CAGR)

Revenue 5Y
8.84%
Profit 5Y
19.30%
Revenue (YoY)
7.40%
Earnings (YoY)
-4.90%

Profitability & Returns

ROCE
76.81%
ROE
62.32%
ROA
38.86%
Profit Margin
24.91%
Op Margin
25.73%
Gross Margin
74.37%
EPS (Latest Qtr)
₹56.99
EPS (TTM)
₹215.19

Balance Sheet & Liquidity

Debt/Equity
1.77
Quick Ratio
1.65
Current Ratio
2.18
Debt
₹9.29 Cr
Total Assets
₹841.35 Cr
Current Assets
₹556.26 Cr
Working Capital
₹301.33 Cr

Ownership

Promoter Holding
52.19%
Chg in Prom Hold
-0.01%
FII / Inst Holding
14.60%
Chg in FII Hold
-2.34%

Financial Snapshot

Enterprise Value
₹8,379.37 Cr
Total Revenue (TTM)
₹1,432.94 Cr
EBITDA
₹466.48 Cr
Free Cash Flow
₹322.28 Cr
Operating Cash Flow
₹337.79 Cr
Shares Outstanding
₹1.66 Cr
Gross Margin
74.37%
Payout Ratio
72.01%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PGHL Procter & Gamble Health Limited NSEPHARMA 5,048.00 23.46 ₹8,379.37 Cr 3.01% 76.81% 62.32% 8.84% 19.30%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --310.99 Cr338.74 Cr324.92 Cr373.86 Cr370.45 Cr
Cost of Revenue --98.72 Cr93.99 Cr68.40 Cr109.82 Cr92.87 Cr
Gross Profit --212.27 Cr244.75 Cr256.52 Cr264.04 Cr277.58 Cr
Operating Expenses --136.72 Cr159.85 Cr142.33 Cr159.48 Cr148.16 Cr
Operating Income --75.55 Cr84.90 Cr114.19 Cr104.56 Cr129.42 Cr
EBITDA --84.03 Cr94.37 Cr125.22 Cr114.82 Cr139.59 Cr
Interest Expense --13.00 L12.00 L12.00 L10.00 L21.00 L
Pretax Income --78.53 Cr88.81 Cr119.02 Cr108.82 Cr133.21 Cr
Tax Provision --17.35 Cr22.63 Cr30.48 Cr31.23 Cr38.61 Cr
Net Income --61.18 Cr66.18 Cr88.54 Cr77.59 Cr94.60 Cr
Diluted EPS --36.8639.8753.5446.7456.99

Profit & Loss (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Revenue -1,092.04 Cr1,205.86 Cr1,129.49 Cr1,407.97 Cr
Cost of Revenue -367.11 Cr392.13 Cr359.49 Cr365.08 Cr
Gross Profit -724.93 Cr813.73 Cr770.00 Cr1,042.89 Cr
Operating Expenses -477.12 Cr517.88 Cr490.89 Cr609.82 Cr
Operating Income -247.81 Cr295.85 Cr279.11 Cr433.07 Cr
EBITDA -280.87 Cr343.07 Cr301.44 Cr474.00 Cr
Interest Expense -42.00 L77.00 L72.00 L55.00 L
Pretax Income -253.37 Cr314.20 Cr273.32 Cr449.86 Cr
Tax Provision -60.85 Cr84.73 Cr72.34 Cr122.95 Cr
Net Income -192.52 Cr229.47 Cr200.98 Cr326.91 Cr
Diluted EPS 107.00116.00138.00121.00-

Balance Sheet (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Total Assets -888.12 Cr1,101.19 Cr794.36 Cr841.35 Cr
Current Assets -608.04 Cr796.10 Cr524.22 Cr556.26 Cr
Cash & Equivalents -319.40 Cr435.05 Cr238.50 Cr177.24 Cr
Inventory -115.21 Cr134.94 Cr109.11 Cr136.65 Cr
Receivables -83.44 Cr115.71 Cr85.33 Cr164.26 Cr
Total Liabilities -271.63 Cr350.30 Cr256.12 Cr316.80 Cr
Current Liabilities -231.90 Cr303.90 Cr218.91 Cr254.93 Cr
Long Term Debt -----
Total Debt -2.83 Cr12.00 Cr9.56 Cr9.29 Cr
Total Equity -616.49 Cr750.89 Cr538.24 Cr524.55 Cr
Shares Outstanding -1.66 Cr1.66 Cr1.66 Cr1.66 Cr

Cash Flows (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Operating Cash Flow -169.52 Cr236.00 Cr228.29 Cr337.79 Cr
Investing Cash Flow --25.54 Cr-21.50 Cr-6.87 Cr1.26 Cr
Financing Cash Flow --288.63 Cr-98.47 Cr-418.11 Cr-343.92 Cr
Capital Expenditure --37.92 Cr-42.48 Cr-21.73 Cr-15.51 Cr
Free Cash Flow -131.60 Cr193.52 Cr206.56 Cr322.28 Cr
Net Change in Cash --144.65 Cr116.03 Cr-196.69 Cr-4.87 Cr

Ratios (Annual)

Figures in %.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Gross Margin % -66.4%67.5%68.2%74.1%
Operating Margin % -22.7%24.5%24.7%30.8%
Net Margin % -17.6%19.0%17.8%23.2%
ROE % -31.2%30.6%37.3%62.3%
ROCE % -37.8%37.1%48.5%73.8%

Shareholding Pattern

Insiders
52.19%
Institutions
14.60%
Public Float
30.54%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PGHL

Google News Mon, 25 May 2026

Is Now The Time To Put Procter & Gamble Health (NSE:PGHL) On Your Watchlist? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOTGpGV0tCbmNpOWhQNWZJZ1dzdzUwZEJJZE5DaTBRU2ZUQzl5Z09IOHhxOXI2ZkZhYnlYakxNRldZb203RklOdGVtV0FWMEFBVlRzT3hobERJS1hWRnVYOXk4ZnI0SlZSM1o3YWxYeENxVDZVOGhON0hoTWZNalR5TVdmVlZCZmRkWk9yZV…

Google News ue, 26 May 2026

Procter & Gamble Health shares rally 19% after strong earnings; check all Q4 numbers - Upstox

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOLUhycEEyb2NLTHhHbVh2djdxalFxTzdBdWNNay10Ylo1LTA5REtwS3EtLWltekFWblRkcUZxNlVhZlVad1Eya1FKRlhhbldTbXFjUnNqbnFrR0twSnNhaVNBb2c5MHpBZjNrWDRPa0Q4OWRfclUwMXlCbWZTQVZXaThkODdmcHNkbE1tdD…

Google News ue, 06 Oct 2026

Procter & Gamble Health (PGHL.NS) Eases 0.47% to ₹5,275, Holding Above ₹5,011 Support - Gap and Go - siam.in

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOaHpLSnRpMGRMemw3aFlUMUJPOXFhSXJzQkFZdU15ODQ3YlNRWTRDRXZYbW1sR2k2SmhyZDRHekNOcVBWaUt1TFFHeW05OXQyS3dFQ3doOWU1QjBqLVVtc1FQODVQMkpRVTBQZHlTMGtaX0pFRUJLU1FZR0lsSkE5dHVkSmlXMmp5anpBRF…

Google News ue, 29 Sep 2026

Procter & Gamble Health Share Price Update and Analysis - Univest

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQX0FJQzlOalRjX08xaEhlb1kxcXlrSElsWDJPYXJhMjVMT0RxLWk1UW40YlhhckYxUF9DRHBldlZRSVdjdjRoeEVmZFZCVGxGSDhaMTFCSmJHOUx6LVlzSDFqal93UXRyRnRMeUYwQnRMa1AwY1JpS1pwbzBWRTlhakFBYTR4UWEtaXVOYW…

Google News Sat, 03 Jan 2026

Procter & Gamble Health Ltd. Share Price Live Today - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOM1ZybEV2aHFzS1VNdUtlOHMwaUY0eGt1c0FyN3R4S2tLLWxXUFEtOWphVmtKY1pWWE9Ga3ZRbnJyYXh3WW1Ub3BvX3NYSjN3NUJBR0ZxOG9hcUw3OVQzQ3dDUm03WFRhQlp5Z0h4clNWYmpvNFgyUWw0QTJtY1dyaDNUMzkxa1J3?oc=5"…

Google News ue, 03 Aug 2021

Procter & Gamble Health Limited (PGHL.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE96NlZnNGxaTVVxclQwYUhHWlBEX3VXV0IxZHdKaHhSa2tCOTRWTW9OMkdhRUFVQXNPbldnODZmM2ZORS1ocm9MZzZOY1dFeXFCVXJHcWFR?oc=5" target="_blank">Procter & Gamble Health Limited (PGHL.NS) Stock Pri…

PGHL — Frequently Asked Questions

What is the current share price of Procter & Gamble Health Limited (PGHL)?

As of 2026-10-23 04:58 IST, Procter & Gamble Health Limited (PGHL) trades at ₹5,048.00 on NSE. Its 52-week range is ₹4,741.31 to ₹6,864.51.

What is the market capitalisation of PGHL?

Procter & Gamble Health Limited (PGHL) has a market capitalisation of ₹8,379.37 Cr on NSE.

What is the P/E ratio of PGHL?

PGHL trades at a trailing price-to-earnings (P/E) ratio of 23.46. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 16.47.

Does PGHL pay a dividend?

Procter & Gamble Health Limited (PGHL) currently offers a dividend yield of 3.01%.

What is the return on equity (ROE) of PGHL?

PGHL has a return on equity (ROE) of 62.32%. Its return on capital employed (ROCE) is 76.81%.

Is PGHL a good stock to buy?

This page provides a data-driven analysis of Procter & Gamble Health Limited (PGHL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space